Clinical Trials Browser

Recruiting × belantamab mafodotin × Clear all

NCT05091372 2026-03-05

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT05145816 2026-02-17

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Phase 1/2 Recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT05847569 2026-02-03

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT05714839 2026-01-23

DREAMM-20

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT04822337 2026-01-20

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05922501 2026-01-14

ISABELA

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT06679101 2026-01-08

DREAMM-10

Phase 3 Recruiting

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT05789303 2025-12-22

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT05055063 2025-12-18

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Phase 1 Recruiting

Neoplasms, Plasma Cell

NCT05002816 2025-10-30

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT05208307 2025-09-02

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT05853965 2025-03-30

BELI(E)VE

Phase 1/2 Recruiting

Multiple Myeloma

NCT05060627 2022-09-08

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

Phase 1/2 Recruiting

Multiple Myeloma